Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration
| Autor: | Bhaskar Gupta, Mohammed Elagouz, Sobha Sivaprasad |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty genetic structures Bevacizumab Eye disease Visual impairment Angiogenesis Inhibitors Antibodies Monoclonal Humanized Ophthalmology medicine Humans Retina Vascular Endothelial Growth Factors business.industry Antibodies Monoclonal Middle Aged Macular degeneration medicine.disease Choroidal Neovascularization eye diseases Surgery Angioid streaks Choroidal neovascularization medicine.anatomical_structure Photochemotherapy Intravitreal Injections Myopia Degenerative Angioid Streaks Female sense organs medicine.symptom business Retinopathy medicine.drug |
| Zdroj: | Eye. 24:203-213 |
| ISSN: | 1476-5454 0950-222X |
| DOI: | 10.1038/eye.2009.201 |
| Popis: | Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|